RxDoctor Payments Data

Vaughn Dobalian, MD

Family Medicine · Jacksonville Beach, FLNPI 1245260199

Payments from drug & device makers

$6,862in general payments, 2019–2025

Across 238 payments — averaging $28.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$619
  • Merck$384
  • Novartis$188
  • plus $939 from 16 others

What the payments were for

  • Food & beverage$6,81499%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,862 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$36,352
Medicare patients
26
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$25,013
JanuviaSitagliptin Phosphate37$21,326
EntrestoSacubitril/Valsartan13$8,469
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,919
EliquisApixaban13$7,051
FarxigaDapagliflozin Propanediol11$6,445
Advair HfaFluticasone Propion/Salmeterol11$4,503
Miglitol12$1,432
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl12$920
Pioglitazone Hcl207$694
Ezetimibe104$692
Omeprazole80$628
Rosuvastatin Calcium156$542
Montelukast Sodium97$427
Atorvastatin Calcium86$425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,156$25,01343 claims
MerckJanuvia$384$21,32637 claims
NovartisEntresto$188$8,46913 claims
PfizerEliquis$14$7,05113 claims
AstraZenecaFarxiga$2,498$6,44511 claims
Lilly USA, LLCOlanzapine$619$12811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →